Prolonged Circulation and Increased Tumor Accumulation of Liposomal Vincristine in a Mouse Model of Rhabdomyosarcoma

References

• Williams RF Fernandez-Pineda I Gosain A . Pediatric sarcomas. Surg. Clin. North Am.96, 1107 – 1125 (2016).
   PubMed Web of Science ®Google Scholar
• Ognjanovic S Linabery AM Charbonneau B Ross JA . Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer115 (18), 4218 – 4226 (2009).
   PubMed Web of Science ®Google Scholar
• Van Gaal JC Van Der Graaf WTA Rikhof B et al. The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. Anticancer Res.32 (10), 4485 – 4498 (2012).
   PubMed Web of Science ®Google Scholar
• Breitfeld PP Meyer WH . Rhabdomyosarcoma: new windows of opportunity. Oncologist10, 518 – 527 (2005).
   PubMed Web of Science ®Google Scholar
• Silverman JA Deitcher SR . Marqibo (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol.71 (3), 555 – 564 (2013).
   PubMed Web of Science ®Google Scholar
• Mayer LD Masin D Nayar R Boman NL Bally MB . Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br. J. Cancer.71 (3), 482 – 488 (1995).
   PubMed Web of Science ®Google Scholar
• Webb MS Harasym TO Masin D Bally MB Mayer LD . Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer72 (4), 896 – 904 (1995).
   PubMed Web of Science ®Google Scholar
• Boman NL Bally MB Cullis PR Mayer LD Webb MS . Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy. J. Liposome Res.5 (3), 523 – 541 (1995).
   Google Scholar
• Johnston MJW Semple SC Klimuk SK et al. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim. Biophys. Acta1758, 55 – 64 (2006).
   PubMed Web of Science ®Google Scholar
• Maeda H Wu J Sawa T Matsumura Y Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release65, 271 – 284 (2000).
   PubMed Web of Science ®Google Scholar
• Fang J Nakamura H Maeda H . The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev.63 (3), 136 – 151 (2011).
   PubMed Web of Science ®Google Scholar
• Yan Z Zhu Z Qian Z et al. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors. Acta Pharmacol. Sin.33, 852 – 858 (2012).
   PubMed Web of Science ®Google Scholar
• Blanco E Shen H Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol.33 (9), 941 – 951 (2015).
   PubMed Web of Science ®Google Scholar
• Immordino ML Dosio F Cattel L . Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine1 (3), 297 – 315 (2006).
   PubMed Web of Science ®Google Scholar
• Allen TM Newman MS Woodle MC Mayhew E Uster PS . Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer.62 (2), 199 – 204 (1995).
   PubMed Web of Science ®Google Scholar
• Allen TM Cullis PR . Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev.65, 36 – 48 (2013).
   PubMed Web of Science ®Google Scholar
• Bertrand N Wu J Xu X Kamaly N Farokhzad OC . Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev.66, 2 – 25 (2014).
   PubMed Web of Science ®Google Scholar
• Luo L-M Huang Y Zhao B-X et al. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials34 (4), 1102 – 1114 (2013).
   PubMed Web of Science ®Google Scholar
• Mitra AK Agrahari V Mandal A et al. Novel delivery approaches for cancer therapeutics. J. Control. Release219, 248 – 268 (2015).
   PubMed Web of Science ®Google Scholar
• Hajdin K D’Alessandro V Niggli FK Schäfer BW Bernasconi M . Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. PLoS ONE5 (5), e10445 (2010).
   PubMed Web of Science ®Google Scholar
• Nakayama K . Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem. J.327, 625 – 635 (1997).
   PubMed Web of Science ®Google Scholar
• Thomas G . Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol.3 (10), 753 – 766 (2002).
   PubMed Web of Science ®Google Scholar
• Khatib AM Siegfried G Prat A et al. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: Importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J. Biol. Chem.276 (33), 30686 – 30693 (2001).
   PubMed Web of Science ®Google Scholar
• Siegfried G Basak A Cromlish JA et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J. Clin. Invest.111, 1723 – 1732 (2003).
   PubMed Web of Science ®Google Scholar
• Remacle A Rozanov D Fugere M Day R Strongin A . Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP. Oncogene25, 5648 – 5655 (2006).
   PubMed Web of Science ®Google Scholar
• Jaaks P D’Alessandro V Grob N et al. The proprotein convertase furin contributes to rhabdomyosarcoma malignancy by promoting vascularization, migration and invasion. PLoS ONE11 (8), e0161396 (2016).
   PubMed Web of Science ®Google Scholar
• Jaaks P Meier G Alijaj N et al. The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells. Oncotarget7 (47), 76743 – 76755 (2016).
   PubMedGoogle Scholar
• Arsenault D Lucien F Dubois CM . Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-Golgi network to the cell surface. J. Cell Physiol.227 (2), 789 – 800 (2012).
   PubMed Web of Science ®Google Scholar
• Nordsmark M Alsner J Keller J et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br. J. Cancer84 (8), 1070 – 1075 (2001).
   PubMed Web of Science ®Google Scholar
• Kim JI Choi KU Lee IS et al. Expression of hypoxic markers and their prognostic significance in soft tissue sarcoma. Oncol. Lett.9 (4), 1699 – 1706 (2015).
   PubMed Web of Science ®Google Scholar
• Wysoczynski M Shin DM Kucia M Ratajczak MZ . Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications. Int. J. Cancer126 (2), 371 – 381 (2010).
   PubMed Web of Science ®Google Scholar
• Kilic M Kasperczyk H Fulda S Debatin K-M . Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene26 (14), 2027 – 2038 (2007).
   PubMed Web of Science ®Google Scholar
• Webb MS Saxon D Wong FMP et al. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim. Biophys. Acta1372, 272 – 282 (1998).
   PubMed Web of Science ®Google Scholar
• Forster V Signorell RD Roveri M Leroux J-C . Liposome-supported peritoneal dialysis for detoxification of drugs and endogenous metabolites. Sci. Transl. Med.6 (258), 258ra141 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang Y Huo M Zhou J Xie S . PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed.99, 306 – 314 (2010).
   PubMed Web of Science ®Google Scholar
• Polomska A Gauthier MA Leroux J-C . In vitro and in vivo evaluation of PEGylated layer-by-layer polyelectrolyte-coated paclitaxel nanocrystals. Small13 (2), doi:10.1002/smll.201602066 (2017) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Almeida AM Castel-Branco MM Falcão AC . Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. J. Chromatogr. B.774, 215 – 222 (2002).
   PubMed Web of Science ®Google Scholar
• Joshi BP Zhou J Pant A et al. Design and synthesis of near-infrared peptide for in vivo molecular imaging of HER2. Bioconjug. Chem.27 (2), 481 – 494 (2016).
   PubMed Web of Science ®Google Scholar
• Taraballi F Natalello A Campione M et al. Glycine-spacers influence functional motifs exposure and self-assembling propensity of functionalized substrates tailored for neural stem cell cultures. Front. Neuroeng.3 (1), doi:10.3389/neuro.16.001.2010 (2010) ( Epub ahead of print).
   PubMedGoogle Scholar
• Sturm MB Joshi BP Lu S et al. Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci. Transl. Med.5 (184), 184ra61 (2013).
   PubMed Web of Science ®Google Scholar
• Wolfenden R Andersson L Cullis PM Southgate CCB . Affinities of amino acid side chains for solvent water. Biochemistry20 (4), 849 – 855 (1981).
   PubMed Web of Science ®Google Scholar
• Molloy SS Bresnahan PA Leppla SH Klimpel KR Thomas G . Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J. Biol. Chem.267 (23), 16396 – 16402 (1992).
   PubMed Web of Science ®Google Scholar
• Henrich S Cameron A Bourenkov GP et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat. Struct. Biol.10 (7), 520 – 526 (2003).
   PubMedGoogle Scholar
• Bourne GL Grainger DJ . Development and characterisation of an assay for furin activity. J. Immunol. Methods364 (1–2), 101 – 108 (2011).
   PubMed Web of Science ®Google Scholar
• Coppola JM Hamilton CA Bhojani MS Larsen MJ Ross BD Rehemtulla A . Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity. Anal. Biochem.364, 19 – 29 (2007).
   PubMed Web of Science ®Google Scholar
• Komiyama T Coppola JM Larsen MJ et al. Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J. Biol. Chem.284 (23), 15729 – 15738 (2009).
   PubMed Web of Science ®Google Scholar
• Cameron A Appel J Houghten RA Lindberg I . Polyarginines are potent furin inhibitors. J. Biol. Chem.275 (47), 36741 – 36749 (2000).
   PubMed Web of Science ®Google Scholar
• Park BW Zhang HT Wu C et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol.18 (2), 194 – 198 (2000).
   PubMed Web of Science ®Google Scholar
• Watson GM Gunzburg MJ Ambaye ND et al. Cyclic peptides incorporating phosphotyrosine mimetics as potent and specific inhibitors of the Grb7 breast cancer target. J. Med. Chem.58 (19), 7707 – 7718 (2015).
   PubMed Web of Science ®Google Scholar
• Ren Y Mu Y Song Y et al. A new peptide ligand for colon cancer targeted delivery of micelles. Drug Deliv.23 (5), 1763 – 1772 (2016).
   PubMed Web of Science ®Google Scholar
• Blanchette F Day R Dong W Laprise M-H Dubois C . TGFβ1 regulates gene expression of its own converting enzyme furin. J. Clin. Invest.99 (8), 1974 – 1983 (1997).
   PubMed Web of Science ®Google Scholar
• McMahon S Grondin F McDonald PP Richard DE Dubois CM . Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J. Biol. Chem.280 (8), 6561 – 6569 (2005).
   PubMed Web of Science ®Google Scholar
• Wilson WR Hay MP . Targeting hypoxia in cancer therapy. Nat. Rev. Cancer11, 393 – 410 (2011).
   PubMed Web of Science ®Google Scholar
• Dubois L Landuyt W Cloetens L et al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur. J. Nucl. Med. Mol. Imaging36 (2), 209 – 218 (2009).
   PubMed Web of Science ®Google Scholar
• Forster V Luciani P Leroux J-C . Treatment of calcium channel blocker-induced cardiovascular toxicity with drug scavenging liposomes. Biomaterials33 (13), 3578 – 3585 (2012).
   PubMed Web of Science ®Google Scholar
• Giger EV Castagner B Räikkönen J Mönkkönen J Leroux JC . siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators. Adv. Healthc. Mater.2 (1), 134 – 144 (2013).
   PubMed Web of Science ®Google Scholar
• Ostrowsky N . Liposome size measurements by photon correlation spectroscopy. Chem. Phys. Lipids64 (1–3), 45 – 56 (1993).
   Web of Science ®Google Scholar
• Cho EC Zhang Q Xia Y . The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles. Nat. Nanotechnol.6 (6), 385 – 391 (2011).
   PubMed Web of Science ®Google Scholar
• Spyrogianni A Herrmann IK Lucas MS Leroux J-C Sotiriou GA . Quantitative analysis of the deposited nanoparticle dose on cell cultures by optical absorption spectroscopy. Nanomedicine11 (19), 2483 – 2496 (2016).
   PubMed Web of Science ®Google Scholar
• Wang F Chen L Zhang R Chen Z Zhu L . RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. J. Control. Release196, 222 – 233 (2014).
   PubMed Web of Science ®Google Scholar
• Dixit S Novak T Miller K Zhu Y Kenney ME Broome A-M . Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale7 (5), 1782 – 1790 (2015).
   PubMed Web of Science ®Google Scholar
• Schiffelers RM Koning GA Ten Hagen TLM et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release91 (1–2), 115 – 122 (2003).
   PubMed Web of Science ®Google Scholar
• Krishna R Webb MS Onge GS Mayer LD . Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J. Pharmacol. Exp. Ther.298 (3), 1206 – 1212 (2001).
   PubMed Web of Science ®Google Scholar
• Song X-L Liu S Jiang Y et al. Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG2000-transferrin in treatment of brain glioma. Eur. J. Pharm. Sci.96, 129 – 140 (2017).
   PubMed Web of Science ®Google Scholar
• Soosay Raj TA Smith AM Moore AS . Vincristine sulfate liposomal injection for acute lymphoblastic leukemia. Int. J. Nanomedicine8, 4361 – 4369 (2013).
   PubMed Web of Science ®Google Scholar
• O’Brien S Schiller G Lister J et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult philadelphia chromosome-negative acute lymphoblastic leukemia. J. Clin. Oncol.31 (6), 676 – 683 (2013).
   PubMed Web of Science ®Google Scholar
• Bedikian AY Silverman JA Papadopoulos NE et al. Pharmacokinetics and safety of marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J. Clin. Pharmacol.51 (8), 1205 – 1212 (2011).
   PubMed Web of Science ®Google Scholar
• Shah NN Merchant MM Cole DE et al. Vincristine sulfate liposomes injection (VSLI, Marqibo®): results from a Phase I study in children, adolescents, and young adults with refractory solid tumors or leukemias. Pediatr. Blood Cancer.63, 997 – 1005 (2016).
   PubMed Web of Science ®Google Scholar
• Xiong XB Huang Y Lu WL et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J. Control. Release107 (2), 262 – 275 (2005).
   PubMed Web of Science ®Google Scholar
• Bartlett DW Su H Hildebrandt IJ Weber Wa Davis ME . Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA104 (39), 15549 – 15554 (2007).
   PubMed Web of Science ®Google Scholar
• Pastorino F Brignole C Marimpietri D et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res.63 (21), 7400 – 7409 (2003).
   PubMed Web of Science ®Google Scholar
• Yoo HS Park TG . Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release96 (2), 273 – 283 (2004).
   PubMed Web of Science ®Google Scholar